Live Breaking News & Updates on Value In Cancer Care Consortium

Stay updated with breaking news from Value in cancer care consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Michael Stebbins

Michael Stebbins
fas.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fas.org Daily Mail and Mail on Sunday newspapers.

Stony Brook , United States , White House , District Of Columbia , Harry Reid , Michael Stebbins , Engineers For America Action Fund , John Arnold Foundation , Cold Spring Harbor Laboratory , Obama White House Office Of Science , Federation Of American Scientists , Board On Research Data , Us Government Invasive Species Advisory Committee Task , Obama Presidential Campaign , National Academies Of Science , Obama White House Transition Team , Value In Cancer Care Consortium , Office Of The President , National Human Genome Research Institute , University Of Pennsylvania , Technology For The Laura , Assistant Director , Obama White House Office , Science Advisors , Executive Orders , Propelling Innovation ,

Experts push for new cancer drug dosing recommendations

This article originally appeared on Undark.
When chatting at cocktail parties about his job, Mark Ratain, an oncologist and pharmacologist at the University of Chicago, often asks a short riddle: Your doctor gives you a prescription for a new drug. The pharmacist says, Make sure you take it on an empty stomach, twice a day. What do you think would happen if you took it with food?
Most don t get the answer right. Nobody would ever say, Well, I could die from an overdose, Ratain says.
Advertisement:
That s exactly what could happen to anyone taking the drug nilotinib approved by the U.S. Food and Drug Administration in 2007 to treat the blood cancer chronic myelogenous leukemia. The drug is among the most effective cancer therapies; a patient taking it may have a 96 percent chance of surviving the cancer for at least six years, according to one of the most recent long-term studies. But the FDA-approved label for nilotinib carries a black box warning: Take i ....

United States , City Of , United Kingdom , Russell Szmulewitz , Javid Moslehi , Daniel Goldstein , Petah Tikva , Clifford Hudis , Mark Ratain , Peter Clark , Chanapa Tantibanchachai , Vanderbilt University Medical Center , American Society Of Clinical Oncology , National Health Service , Office Of Hematology , Journal Of The American College Cardiology , University Of Chicago , First International Summit On Interventional Pharmacoeconomics , Rabin Medical Center , House Committee On Oversight , National Comprehensive Cancer Network , Members Of Congress , Drug Administration , World Health Organization , Value In Cancer Care Consortium , National Institute For Health ,

Experts Push for New Cancer Drug Dosing Recommendations

Experts Push for New Cancer Drug Dosing Recommendations
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

United States , City Of , United Kingdom , Russell Szmulewitz , Javid Moslehi , Daniel Goldstein , Petah Tikva , Clifford Hudis , Mark Ratain , Peter Clark , Chanapa Tantibanchachai , Vanderbilt University Medical Center , American Society Of Clinical Oncology , National Health Service , Office Of Hematology , Journal Of The American College Cardiology , University Of Chicago , First International Summit On Interventional Pharmacoeconomics , Rabin Medical Center , House Committee On Oversight , National Comprehensive Cancer Network , Members Of Congress , Drug Administration , World Health Organization , Value In Cancer Care Consortium , National Institute For Health ,